SCHEMBL2993048

SCHEMBL2993048

CCOc1cc(C(=O)NN)ccn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.49
MPO P05164 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
ADORA3 P0DMS8 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2A6 P11509 1/20 0.49
CYP2C19 P33261 1/20 0.49
PROKR1 Q8TCW9 1/20 0.44
KCNK3 O14649 1/20 0.43
KCNK9 Q9NPC2 1/20 0.43
AURKA O14965 1/20 0.42
RPS6KB1 P23443 1/20 0.42
AURKB Q96GD4 1/20 0.42
ACACB O00763 1/20 0.42
KMT2A Q03164 1/20 0.42
MAPT P10636 2/20 0.42
CTSA P10619 1/20 0.42
ALDH1A1 P00352 2/20 0.42
NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31384302 0.85 KCNK3 (0.57) KDM4EMPOCYP1A2CYP3A4ADORA3
SCHEMBL2969846 0.85 KCNK3 (0.57) KDM4EMPOCYP1A2CYP3A4ADORA3
SCHEMBL6241029 0.83 PARP10 (0.51) PROKR1AURKARPS6KB1AURKBACACB
SCHEMBL30281260 0.83 PARP10 (0.51) PROKR1AURKARPS6KB1AURKBACACB
SCHEMBL29173821 0.82 KDM4E (0.55) KDM4EPROKR1ACACBMAPTALDH1A1
SCHEMBL30723841 0.81 MAPT (0.57) KDM4EPROKR1KMT2AMAPTALDH1A1
SCHEMBL1992514 0.81 MAPT (0.57) KDM4EPROKR1KMT2AMAPTALDH1A1
SCHEMBL14480077 0.81 CREBBP (0.50) PROKR1ACACBKMT2AMAPTALDH1A1
SCHEMBL25166967 0.81 KDM4E (0.49) KDM4EMPOCYP1A2CYP3A4ADORA3
SCHEMBL17478456 0.80 MAPT (0.56) KDM4EPROKR1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100184811-A1 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS BRIDGE BIORESEARCH RIGHTS (JERSEY) LIMITED (GB) 2010-07-22 US disclosed
EP-2068873-A2 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS Pharma 2100 (DK) 2009-06-17 EP disclosed
WO-2008031440-A2 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS PHARMA 2100 (DK) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184811-A1 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS ODC1, OTC, ACACB KDM4E 3169/4885MPO 582/4885CYP1A2 385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.